[HTML][HTML] Recent advances in CAR-T cell engineering
R Huang, X Li, Y He, W Zhu, L Gao, Y Liu… - Journal of hematology & …, 2020 - Springer
Chimeric antigen receptor T (CAR-T) cell therapy is regarded as an effective solution for
relapsed or refractory tumors, particularly for hematological malignancies. Although the …
relapsed or refractory tumors, particularly for hematological malignancies. Although the …
[HTML][HTML] Recent advances in CAR-T cell engineering
R Huang, X Li, Y He, W Zhu, L Gao, Y Liu… - … of Hematology & …, 2020 - ncbi.nlm.nih.gov
Chimeric antigen receptor T (CAR-T) cell therapy is regarded as an effective solution for
relapsed or refractory tumors, particularly for hematological malignancies. Although the …
relapsed or refractory tumors, particularly for hematological malignancies. Although the …
[HTML][HTML] Recent advances in CAR-T cell engineering
R Huang, X Li, Y He, W Zhu… - … of Hematology & …, 2020 - jhoonline.biomedcentral.com
Chimeric antigen receptor T (CAR-T) cell therapy is regarded as an effective solution for
relapsed or refractory tumors, particularly for hematological malignancies. Although the …
relapsed or refractory tumors, particularly for hematological malignancies. Although the …
Recent advances in CAR-T cell engineering.
R Huang, X Li, Y He, W Zhu, L Gao, Y Liu… - Journal of Hematology …, 2020 - go.gale.com
Chimeric antigen receptor T (CAR-T) cell therapy is regarded as an effective solution for
relapsed or refractory tumors, particularly for hematological malignancies. Although the …
relapsed or refractory tumors, particularly for hematological malignancies. Although the …
Recent advances in CAR-T cell engineering.
R Huang, X Li, Y He, W Zhu, L Gao, Y Liu… - … of Hematology & …, 2020 - europepmc.org
Chimeric antigen receptor T (CAR-T) cell therapy is regarded as an effective solution for
relapsed or refractory tumors, particularly for hematological malignancies. Although the …
relapsed or refractory tumors, particularly for hematological malignancies. Although the …
[引用][C] Recent advances in CAR-T cell engineering
R Huang, X Li, Y He, W Zhu, L Gao, Y Liu… - … of Hematology & …, 2020 - jglobal.jst.go.jp
J Hematol Oncol; CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic
leukemia: factors affecting toxicities and long-term efficacies; LN Zhang, Y Song, D Liu; 11; …
leukemia: factors affecting toxicities and long-term efficacies; LN Zhang, Y Song, D Liu; 11; …
[PDF][PDF] Recent advances in CAR-T cell engineering
R Huang, X Li, Y He, W Zhu, L Gao, Y Liu, L Gao… - 2020 - scholar.archive.org
Chimeric antigen receptor T (CAR-T) cell therapy is regarded as an effective solution for
relapsed or refractory tumors, particularly for hematological malignancies. Although the …
relapsed or refractory tumors, particularly for hematological malignancies. Although the …
Recent advances in CAR-T cell engineering
R Huang, X Li, Y He, W Zhu, L Gao… - … of hematology & …, 2020 - pubmed.ncbi.nlm.nih.gov
Chimeric antigen receptor T (CAR-T) cell therapy is regarded as an effective solution for
relapsed or refractory tumors, particularly for hematological malignancies. Although the …
relapsed or refractory tumors, particularly for hematological malignancies. Although the …
Recent advances in CAR-T cell engineering.
R Huang, X Li, Y He, W Zhu, L Gao… - … of Hematology & …, 2020 - search.ebscohost.com
Chimeric antigen receptor T (CAR-T) cell therapy is regarded as an effective solution for
relapsed or refractory tumors, particularly for hematological malignancies. Although the …
relapsed or refractory tumors, particularly for hematological malignancies. Although the …
Recent advances in CAR-T cell engineering
R Huang, X Li, Y He, W Zhu, L Gao, Y Liu… - Journal of Hematology …, 2020 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Chimeric antigen receptor T (CAR-T) cell
therapy is regarded as an effective solution for relapsed or refractory tumors, particularly for …
therapy is regarded as an effective solution for relapsed or refractory tumors, particularly for …